John M. Burke, MD, examines how new obesity treatments, such as GLP-1 agonists, might influence future cancer rates.

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

About 154 million non-elderly Americans rely on employer-sponsored coverage, and the 26th annual survey of more than 2,100 ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Inventive deal structures are on the rise within China’s life sciences industry, with the “NewCo” model having garnered significant interest ...

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

Zealand Pharma CEO Adam Steensberg said Friday that the company is working on a next-generation weight loss drug that’s ...

Health-care costs are going up and and yet, workers may still not get the coverage they want — particularly when it comes to drugs like Ozempic.

Friendships forged during a person's turbulent teenage years lay the essential foundation for their happiness later in life, ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...